704 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
AbbVie's Humira Gains FDA Approval for Label Expansion http://www.zacks.com/stock/news/189834/abbvies-humira-gains-fda-approval-for-label-expansion?cid=CS-ZC-FT-189834 Sep 11, 2015 - AbbVie (ABBV) gained ninth FDA approval for Humira for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa.
Why is Gilead (GILD) Raising a Whopping $10 Billion? http://www.zacks.com/stock/news/189833/why-is-gilead-gild-raising-a-whopping-%2410-billion?cid=CS-ZC-FT-189833 Sep 11, 2015 - Gilead Sciences, Inc. (GILD) announced successful pricing of its senior note offering worth $10 billion in aggregate principal amount.
Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up http://www.zacks.com/stock/news/188930/bristol-myers-bmy-opdivo-gets-priority-review-shares-up?cid=CS-ZC-FT-188930 Sep 03, 2015 - Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for Opdivo has been accepted with priority review by the FDA.
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review http://www.zacks.com/stock/news/188749/bristol-myers-abbvie-cancer-drug-gets-priority-review?cid=CS-ZC-FT-188749 Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.

Pages: 1...666768697071

<<<Page 71